Načítá se...
Inhibitors of the AAA+ Chaperone p97
It is remarkable that a pathway as ubiquitous as protein quality control can be targeted to treat cancer. Bortezomib, an inhibitor of the proteasome, was first approved by the US Food and Drug Administration (FDA) more than 10 years ago to treat refractory myeloma and later extended to lymphoma. Its...
Uloženo v:
| Vydáno v: | Molecules |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4576884/ https://ncbi.nlm.nih.gov/pubmed/25685910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules20023027 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|